Get the Stockscreener App
54.90
0.63%
-0.35
After Hours:
55.20
0.30
+0.55%
Anaptysbio Inc stock is traded at $54.90, with a volume of 677.78K.
It is down -0.63% in the last 24 hours and up +11.97% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$55.25
Open:
$55.3
24h Volume:
677.78K
Relative Volume:
1.24
Market Cap:
$1.52B
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-9.0296
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+14.61%
1M Performance:
+11.97%
6M Performance:
+173.00%
1Y Performance:
+239.94%
1-Day Range:
$51.92
$56.07
1-Week Range:
$46.85
$56.39
52-Week Range:
$14.46
$56.39
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
54.90 | 1.53B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Page not foundAirwhon - MarketBeat
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - Yahoo Finance
ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline - TradingView
AnaptysBio stock hits 52-week high at $52.56 By Investing.com - Investing.com South Africa
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance
(ANAB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Market Trends: Is AnaptysBio Inc a momentum stockDollar Strength & Real-Time Stock Price Movement Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighShould You Buy? - MarketBeat
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts - MarketBeat
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte, Novartis - Barchart.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Momentum Shift: Is AnaptysBio Inc in a consolidation phase2025 Dividend Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anaptys Announces Participation at Upcoming Investor Conferences - Sahm
Biotech firm Anaptys lines up February–March investor events - Stock Titan
AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics. - Longbridge
Sentiment Review: Is GTIM in a long term uptrendJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Biotech Leader Eyes Spinoff Amid Massive Sales Surge - Investor's Business Daily
Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Responsive Playbooks and the ANAB Inflection - Stock Traders Daily
Inflation Data: Will BTCT benefit from rising consumer demandWeekly Stock Analysis & Verified Swing Trading Watchlist - baoquankhu1.vn
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
Can AnaptysBio Inc. reach all time highs this yearQuarterly Trade Summary & Daily Stock Trend Reports - mfd.ru
Bear Alert: Is AnaptysBio Inc undervalued by DCF analysisDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup - ChartMill
Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects - Sahm
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Understanding the Setup: (ANAB) and Scalable Risk - Stock Traders Daily
Treasury Yields: Will AnaptysBio Inc benefit from geopolitical trendsJuly 2025 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Barclays Raises Price Target for AnaptysBio (ANAB) to $78.00 | A - GuruFocus
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative? - simplywall.st
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS
Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat
Anaptysbio director Marquet sells $530k in shares - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat
Rally Mode: Is AnaptysBio Inc a momentum stock2025 Winners & Losers & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat
ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Australia
What Investors Should Know About a $163K AnaptysBio Insider Sale - sharewise.com
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):